Key Highlights

  • iShares iBonds Dec 2028 Term Corporate ETF tracks the Bloomberg December 2028 Maturity Corporate Index, with exposure to investment-grade U.S.-dollar corporate bonds maturing in 2028.
  • The fund reported 739 holdings and an expense ratio of 0.10%.
  • The fund's disclosed holdings and investment framework describe defined-maturity corporate bond exposure; historic return figures are excluded.

On Oct 27, 2026, iShares iBonds Dec 2028 Term Corporate ETF (NYSEARCA:IBDT) recorded a closing price of USD 25.00. The fund is designed around investment-grade U.S.-dollar corporate bonds maturing in 2028 and uses the Bloomberg December 2028 Maturity Corporate Index as its reference benchmark. Its composition is best understood through the selection framework, the securities it holds and the fund characteristics accompanying the disclosed portfolio. Rather than describing historic share-price movements, this article examines its current exposure and the practical structure of the ETF.

How the Portfolio Is Constructed

IBDT holds investment-grade corporate bonds that fit a specified maturity-year index. Unlike a conventional perpetual-duration bond ETF, its portfolio is organised around bonds scheduled to mature in 2028, with liquidation associated with the term structure described for the product. Credit quality, coupon terms and issuer concentration remain relevant portfolio features.

The stated benchmark, Bloomberg December 2028 Maturity Corporate Index, defines the fund’s investment universe. Within that framework, iShares iBonds Dec 2028 Term Corporate ETF supplies exchange-traded exposure to investment-grade U.S.-dollar corporate bonds maturing in 2028. The distinction between the benchmark and the fund matters: the benchmark describes the selection and weighting framework, while the ETF holds a portfolio of securities intended to implement it. Actual constituents and weights may vary as the relevant index changes.

Holdings and Sector Exposure

CVS Health, Pfizer Investment Enterprises, Amgen, Cigna, AerCap Ireland Capital, Salesforce, Morgan Stanley and Nvidia feature among the disclosed issuers. These positions illustrate issuer diversification across healthcare, technology, financial services and aviation leasing.

Duration and maturity measures summarise the bond portfolio’s interest-rate exposure and timing. Yield to maturity is a portfolio characteristic based on current bond pricing and assumptions, not a guarantee of what a fund shareholder will receive.

Fund Size, Costs and Trading Characteristics

The supplied fund data identifies net fund assets of $4,129,121,427, 739 reported holdings, an expense ratio of 0.10% and a listing on NYSE Arca. These details describe the fund at the reported reference dates rather than results earned by an investor. Net assets provide a measure of scale, the holdings count indicates the number of portfolio positions, and the fee figure describes a recurring fund cost.

For this fixed-income portfolio, duration and yield-to-maturity figures describe different aspects of the bonds held. Effective duration was reported at 1.50 yrs. Average yield to maturity was 5.18%. Neither figure is a realised investor return, and both can change with portfolio composition and bond markets.

Portfolio Details to Monitor

Constituent additions and removals, changes in relative holdings weights and adjustments to the Bloomberg December 2028 Maturity Corporate Index can alter exposure over time. The fund’s published portfolio characteristics should be read with their reporting dates because holdings information and closing prices may come from different dates. Those distinctions preserve the difference between a current portfolio description and any historical performance measure.